Invesco’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.02B Sell
3,905,109
-6,387
-0.2% -$4.89M 0.29% 49
2025
Q4
$3.02B Buy
3,911,496
+2,427,023
+163% +$1.65B 0.28% 52
2025
Q3
$835M Buy
1,484,473
+408,649
+38% +$231M 0.13% 161
2025
Q2
$565M Buy
1,075,824
+225,078
+26% +$126M 0.1% 238
2025
Q1
$540M Sell
850,746
-13,503
-2% -$9.29M 0.1% 233
2024
Q4
$616M Sell
864,249
-296,924
-26% -$249M 0.11% 201
2024
Q3
$1.22B Buy
1,161,173
+244,753
+27% +$272M 0.24% 68
2024
Q2
$963M Sell
916,420
-69,648
-7% -$67.5M 0.2% 88
2024
Q1
$949M Buy
986,068
+221,061
+29% +$210M 0.2% 87
2023
Q4
$672M Buy
765,007
+21,659
+3% +$17.8M 0.16% 133
2023
Q3
$612M Sell
743,348
-165,714
-18% -$130M 0.16% 134
2023
Q2
$653M Buy
909,062
+24,307
+3% +$18.7M 0.17% 121
2023
Q1
$727M Buy
884,755
+191,892
+28% +$145M 0.2% 98
2022
Q4
$500M Buy
692,863
+51,541
+8% +$38M 0.15% 160
2022
Q3
$442M Buy
641,322
+13,135
+2% +$8.27M 0.14% 170
2022
Q2
$371M Buy
628,187
+25,256
+4% +$16.4M 0.11% 223
2022
Q1
$421M Buy
602,931
+14,720
+3% +$9.31M 0.11% 239
2021
Q4
$371M Buy
588,211
+103,773
+21% +$63.8M 0.09% 287
2021
Q3
$293M Buy
484,438
+25,958
+6% +$16.1M 0.07% 345
2021
Q2
$256M Sell
458,480
-10,864
-2% -$5.5M 0.06% 400
2021
Q1
$222M Buy
469,344
+70,883
+18% +$34.5M 0.06% 416
2020
Q4
$193M Buy
398,461
+108,214
+37% +$58.4M 0.06% 443
2020
Q3
$162M Buy
290,247
+31,119
+12% +$18.9M 0.05% 432
2020
Q2
$162M Sell
259,128
-43,407
-14% -$24.6M 0.06% 405
2020
Q1
$148M Sell
302,535
-6,820
-2% -$2.81M 0.06% 371
2019
Q4
$116M Sell
309,355
-1,002,899
-76% -$337M 0.04% 594
2019
Q3
$364M Sell
1,312,254
-32,019
-2% -$9.47M 0.1% 235
2019
Q2
$421M Buy
1,344,273
+46,055
+4% +$15.3M 0.11% 216
2019
Q1
$533M Buy
1,298,218
+66,786
+5% +$27.5M 0.18% 123
2018
Q4
$460M Buy
1,231,432
+19,546
+2% +$7.15M 0.18% 128
2018
Q3
$490M Buy
1,211,886
+67,071
+6% +$25.5M 0.15% 148
2018
Q2
$395M Buy
1,144,815
+108,565
+10% +$34M 0.13% 173
2018
Q1
$357M Buy
1,036,250
+73,355
+8% +$25.5M 0.13% 175
2017
Q4
$362M Buy
962,895
+65,519
+7% +$26.5M 0.13% 184
2017
Q3
$401M Sell
897,376
-33,253
-4% -$15.8M 0.15% 165
2017
Q2
$457M Buy
930,629
+244
+0% +$107K 0.14% 158
2017
Q1
$361M Buy
930,385
+42,057
+5% +$15.6M 0.12% 190
2016
Q4
$326M Buy
888,328
+41,562
+5% +$15.8M 0.11% 209
2016
Q3
$340M Buy
846,766
+22,483
+3% +$9.02M 0.12% 200
2016
Q2
$288M Sell
824,283
-179,634
-18% -$69.2M 0.11% 220
2016
Q1
$362M Sell
1,003,917
-282,066
-22% -$116M 0.15% 159
2015
Q4
$698M Buy
1,285,983
+234,111
+22% +$127M 0.28% 67
2015
Q3
$489M Buy
1,051,872
+565
+0.1% +$303K 0.21% 100
2015
Q2
$536M Sell
1,051,307
-19,322
-2% -$9.43M 0.21% 102
2015
Q1
$483M Sell
1,070,629
-212,853
-17% -$90.2M 0.19% 115
2014
Q4
$527M Buy
1,283,482
+134,855
+12% +$53M 0.2% 112
2014
Q3
$414M Buy
1,148,627
+8,748
+0.8% +$2.93M 0.17% 135
2014
Q2
$322M Sell
1,139,879
-184,552
-14% -$54.7M 0.13% 192
2014
Q1
$398M Buy
1,324,431
+81,757
+7% +$25.2M 0.16% 139
2013
Q4
$342M Buy
1,242,674
+18,862
+2% +$5.43M 0.14% 164
2013
Q3
$383M Buy
1,223,812
+166,914
+16% +$43.9M 0.17% 124
2013
Q2
$238M Buy
+1,056,898
New +$246M 0.11% 207

Other funds holding REGN

Invesco's REGN Position: Q1 2026 in Review

Invesco reduced its Regeneron Pharmaceuticals (REGN) stake by 0.16% in Q1 2026, selling an estimated $4.89M and leaving 3,905,109 shares worth $3.02B. The position accounts for 0.29% of the portfolio, ranked #49.

Invesco first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.02B in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Invesco held 3,905,109 shares of Regeneron Pharmaceuticals worth $3.02B as of Q1 2026.
  • Invesco sold 6,387 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.89M.
  • Regeneron Pharmaceuticals made up 0.29% of Invesco's portfolio in Q1 2026, its #49 holding.
  • Invesco first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Invesco's Regeneron Pharmaceuticals position peaked at $3.02B in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.